The FDA has cleared the investigational new drug (IND) application for NPX372, a first-in-class T-cell engager (TCE) for the ...

FDA approves pembrolizumab with chemotherapy for platinum-resistant ovarian cancer, showing significant survival benefits in ...

Usmani, MD, MBA, discussed the significance of phase 1 outcomes of gintemetostat therapy for patients with heavily pretreated ...

The central finding was the superior activity of a 2-antibody combination against the type 1 mutant CALR neoantigen. Dual ...

SEER-Medicare data show just 4% of older adults with blood cancers enter clinical trials, revealing disparities and fixable ...

Pellini notes that Hispanic patients often exhibit a higher incidence of specific genomic alterations in their cancers.

Rintatolimod (Ampligen) combined with durvalumab (Imfinzi) has continued to exhibit encouraging efficacy, safety, and ...

Patients treated with ciltacabtagene autoleucel (cilta-cel; Carvykti) in the phase 3 CARTITUDE-4 trial (NCT04181827) achieved high rates of progression-free survival (PFS) at nearly 3 years, according ...

The FDA has granted priority review to the supplemental biologics license application for datopotamab deruxtecan (Dato-DXd) ...

Community oncology plays a central role in the US health care system, offering high-quality care that is both accessible and ...

SEER-Medicare data show just 4% of older adults with blood cancers enter clinical trials, revealing disparities and fixable ...

Although patients who received tumor-infiltrating lymphocyte (TIL) therapy had favorable overall survival (OS), a significant number who were evaluated to receive lifileucel (Amtagvi) did not get ...